"bms" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonPharmaceutical research and development pipeline - Bristol Myers Squibb
Pharmaceutical research and development pipeline Bristol Myers Squibb
BMS Beats Again Despite Eliquis and Cobenfy Disappointments - BioSpace
BMS Beats Again Despite Eliquis and Cobenfy Disappointments BioSpace
BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop - Fierce Ph...
BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop Fierce Pharma
BMS reports flat revenue growth for full-year 2025 - Pharmaceutical Technology
BMS reports flat revenue growth for full-year 2025 Pharmaceutical Technology
Racing BMS and J&J, Bayer ties asundexian to 26% stroke decrease - Fierce Biotech
Racing BMS and J&J, Bayer ties asundexian to 26% stroke decrease Fierce Biotech
Eliquis price cut drives upbeat guidance for BMS - FirstWord Pharma
Eliquis price cut drives upbeat guidance for BMS FirstWord Pharma
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts - Investing.com
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts Investing.com
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026 (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026 (NYSE:BMY) Seeking Alpha
Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s - statnews.com
Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s statnews.com
OXB and BMS Expand Partnership With Lentiviral Vectors for CAR-T Programs - Contract Pharma
OXB and BMS Expand Partnership With Lentiviral Vectors for CAR-T Programs Contract Pharma
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025 - Business Wire
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025 Business Wire
Roundup: Y & Parkinson’s, Library & Financial Planning, BMS & Hunger … - 06880 | Where Westport m...
Roundup: Y & Parkinson’s, Library & Financial Planning, BMS & Hunger … 06880 | Where Westport meets the world
BMS 7th Grade Tops ND - WRBI Radio
BMS 7th Grade Tops ND WRBI Radio
With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm - Fierc...
With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm Fierce Pharma
About us - Bristol Myers Squibb
About us Bristol Myers Squibb
BMS pens $850M solid tumor pact with T-cell engager biotech Janux - Fierce Biotech
BMS pens $850M solid tumor pact with T-cell engager biotech Janux Fierce Biotech
OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts - Fierce Pharma
OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts Fierce Pharma
Transparency & reporting - Bristol Myers Squibb
Transparency & reporting Bristol Myers Squibb
BMS snags top neuro researcher from Eisai—Chutes & Ladders - Fierce Biotech
BMS snags top neuro researcher from Eisai—Chutes & Ladders Fierce Biotech
BMS celebrates US soccer legend's shutout against cancer in Breyanzi collab - Fierce Pharma
BMS celebrates US soccer legend's shutout against cancer in Breyanzi collab Fierce Pharma
Former USMNT goalie Kasey Keller goes public about cancer journey in BMS campaign - Medical Marke...
Former USMNT goalie Kasey Keller goes public about cancer journey in BMS campaign Medical Marketing and Media
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments BioSpace
Worldwide locations - Bristol Myers Squibb
Worldwide locations Bristol Myers Squibb
BMS Teacher of the Year arrested on child sex abuse charges - KATC
BMS Teacher of the Year arrested on child sex abuse charges KATC
Areas of interest - Bristol Myers Squibb
Areas of interest Bristol Myers Squibb
Global Inclusion - Bristol Myers Squibb
Global Inclusion Bristol Myers Squibb
Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth - The Wall Street Journal
Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth The Wall Street Journal
Become a business supplier - Bristol Myers Squibb
Become a business supplier Bristol Myers Squibb
Our research in immunology - Bristol Myers Squibb
Our research in immunology Bristol Myers Squibb
Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis - Fie...
Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis Fierce Biotech
Global Patient Week - Bristol Myers Squibb
Global Patient Week Bristol Myers Squibb
Champions in Care - Bristol Myers Squibb
Champions in Care Bristol Myers Squibb
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff - Clinical Trials Arena
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff Clinical Trials Arena
Independent research - Bristol Myers Squibb
Independent research Bristol Myers Squibb
Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B - Fierce ...
Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B Fierce Biotech
OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb - GlobeNewswire
OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb GlobeNewswire
Our technologies - Bristol Myers Squibb
Our technologies Bristol Myers Squibb
Bristol-Myers Squibb Q4 2025 Earnings Preview (BMY:NYSE) - Seeking Alpha
Bristol-Myers Squibb Q4 2025 Earnings Preview (BMY:NYSE) Seeking Alpha
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour - BioSpace
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour BioSpace
Doctorx Unscripted Bold Conversations about Patient-Driven Science - Bristol Myers Squibb
Doctorx Unscripted Bold Conversations about Patient-Driven Science Bristol Myers Squibb
Our research in neuroscience - Bristol Myers Squibb
Our research in neuroscience Bristol Myers Squibb
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immun...
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi - Bus...
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi Business Wire
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy...
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) Bristol Myers Squibb
Chris Shibutani, MD - Bristol Myers Squibb
Chris Shibutani, MD Bristol Myers Squibb
BMS' Cobenfy TV ad is latest target of FDA untitled letter spree - Fierce Pharma
BMS' Cobenfy TV ad is latest target of FDA untitled letter spree Fierce Pharma
Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off - PharmaLive
Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off PharmaLive
Driving patient-centric care through global patient outreach - Bristol Myers Squibb
Driving patient-centric care through global patient outreach Bristol Myers Squibb
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line - BioSpace
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line BioSpace
Business development leadership team - Bristol Myers Squibb
Business development leadership team Bristol Myers Squibb
BMS plots another DTC platform, this one offering Sotyktu at 86% discount to cash-pay patients - ...
BMS plots another DTC platform, this one offering Sotyktu at 86% discount to cash-pay patients Fierce Pharma
Texas files suit against Sanofi, BMS over 'deceptive' Plavix marketing - Fierce Pharma
Texas files suit against Sanofi, BMS over 'deceptive' Plavix marketing Fierce Pharma
Science Firsthand: The renaissance of neuroscience R&D - Bristol Myers Squibb
Science Firsthand: The renaissance of neuroscience R&D Bristol Myers Squibb
BMS expands CAR-T portfolio with $1.5bn Orbital buyout - Pharmaceutical Technology
BMS expands CAR-T portfolio with $1.5bn Orbital buyout Pharmaceutical Technology
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities” - Clinical Trials Arena
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities” Clinical Trials Arena
BMS Makes $1.5B Cell Therapy Play With Orbital Takeover - BioSpace
BMS Makes $1.5B Cell Therapy Play With Orbital Takeover BioSpace
New RayzeBio hub accelerates next-gen cancer therapies - Bristol Myers Squibb
New RayzeBio hub accelerates next-gen cancer therapies Bristol Myers Squibb
Honoring oncologists through the Time Back campaign - Bristol Myers Squibb
Honoring oncologists through the Time Back campaign Bristol Myers Squibb
Border 2 Box Office Day 16 BMS Sales: Sunny Deol's 3rd Saturday Roars With 107% Jump Already - Th...
BMS and Takeda dive into AI data pool, joining peers in collaborative push to unfold the future -...
BMS and Takeda dive into AI data pool, joining peers in collaborative push to unfold the future Fierce Biotech
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical R...
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn European Pharmaceutical Review
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
The Bristol Myers Squibb Foundation Bristol Myers Squibb
BMS sells controlling stake in historic US-China pharmaceutical joint venture - Fierce Pharma
BMS sells controlling stake in historic US-China pharmaceutical joint venture Fierce Pharma
Rovi acquires BMS facility in Phoenix and strikes $250M manufacturing deal - Fierce Pharma
Rovi acquires BMS facility in Phoenix and strikes $250M manufacturing deal Fierce Pharma
With site 'irregularities,' Bristol Myers delays key Cobenfy readout in Alzheimer's psychosis - F...
With site 'irregularities,' Bristol Myers delays key Cobenfy readout in Alzheimer's psychosis Fierce Pharma
People and business resource groups - Bristol Myers Squibb
People and business resource groups Bristol Myers Squibb
BMS, Bain Capital team up on autoimmune-focused newco - FirstWord Pharma
BMS, Bain Capital team up on autoimmune-focused newco FirstWord Pharma
BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study - BioSpace
BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study BioSpace
BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes - Fierce Biotech
BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes Fierce Biotech
BMS and Bain Capital forge $300m immunology spinoff - Pharmaceutical Technology
BMS and Bain Capital forge $300m immunology spinoff Pharmaceutical Technology
A global journey through BMS’ R&D hubs - Bristol Myers Squibb
A global journey through BMS’ R&D hubs Bristol Myers Squibb
Merck & Co., BMS to lay off over 300 staffers in New Jersey - FirstWord Pharma
Merck & Co., BMS to lay off over 300 staffers in New Jersey FirstWord Pharma
BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia - Fier...
BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia Fierce Biotech
BMS boosts cancer trials with Sarah Cannon's clinical research platform - Fierce Biotech
BMS boosts cancer trials with Sarah Cannon's clinical research platform Fierce Biotech
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant - BioSpace
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant BioSpace
Bristol Myers Squibb CDTO Greg Meyers on biopharma’s AI-enabled future - McKinsey & Company
Bristol Myers Squibb CDTO Greg Meyers on biopharma’s AI-enabled future McKinsey & Company
BMS ups guidance, but its financial prospects fail to capture investor enthusiasm - FirstWord Pharma
BMS ups guidance, but its financial prospects fail to capture investor enthusiasm FirstWord Pharma
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC - BioSpace
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC BioSpace
ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage tr...
ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage trial Fierce Biotech
Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer t...
Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test Fierce Biotech
BMS scores 5th indication for Breyanzi with FDA marginal zone lymphoma nod - Fierce Pharma
BMS scores 5th indication for Breyanzi with FDA marginal zone lymphoma nod Fierce Pharma
BMS builds a 'world of gratitude' to honor healthcare workers in new PSA - Fierce Pharma
BMS builds a 'world of gratitude' to honor healthcare workers in new PSA Fierce Pharma
Clinical trials & studies - Bristol Myers Squibb
Clinical trials & studies Bristol Myers Squibb
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy - BioSpace
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy BioSpace
BMS direct platform adds psoriasis drug Sotyktu with deep price cut - FirstWord Pharma
BMS direct platform adds psoriasis drug Sotyktu with deep price cut FirstWord Pharma
BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates...
BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates BioSpace
C2C4C marks 12 inspiring years advancing cancer research - Bristol Myers Squibb
C2C4C marks 12 inspiring years advancing cancer research Bristol Myers Squibb
Our science - Bristol Myers Squibb
Our science Bristol Myers Squibb
FDA Action Alert: BMS, GSK, Amgen and More - BioSpace
JPM26, Day 1: Bristol Myers CEO touts portfolio of blockbuster hopefuls - Fierce Pharma
JPM26, Day 1: Bristol Myers CEO touts portfolio of blockbuster hopefuls Fierce Pharma
BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence - Fierce Biotech
BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence Fierce Biotech
BMS’ Phase III trial of Reblozyl misses primary endpoint - Clinical Trials Arena
BMS’ Phase III trial of Reblozyl misses primary endpoint Clinical Trials Arena
Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma - Fierce Biotech
Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma Fierce Biotech
Bristol Myers Squibb paves way for expansion of Camzyos to adolescent patients - Fierce Pharma
Bristol Myers Squibb paves way for expansion of Camzyos to adolescent patients Fierce Pharma
Rovi’s injectables CDMO rebrands as Rois and acquires BMS facility - European Pharmaceutical Review
Rovi’s injectables CDMO rebrands as Rois and acquires BMS facility European Pharmaceutical Review
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital - Pharma...
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital Pharmaceutical Executive
Bristol Myers Squibb to buy RNA start-up for $1.5 billion - C&EN
Bristol Myers Squibb to buy RNA start-up for $1.5 billion C&EN
BMS Holdings Berhad Sets To Raise RM80.08 Million From Ace Market IPO Exercise - Yahoo Finance
BMS Holdings Berhad Sets To Raise RM80.08 Million From Ace Market IPO Exercise Yahoo Finance
In UK, Big Pharma pressure campaign rolls on as Bristol Myers plans US-level pricing for Cobenfy ...
In UK, Big Pharma pressure campaign rolls on as Bristol Myers plans US-level pricing for Cobenfy Fierce Pharma
Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial - statnews.com
Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial statnews.com